NHS Framework for Midlands and East, Branded Medicines – Tranche A and Annual
A Contract Award Notice
by THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £1
- Sector
- HEALTH
- Published
- 22 Feb 2022
- Delivery
- not specified
- Deadline
- n/a
Related Terms
Location
East Midlands England: Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points
Geochart for 1 buyers and 39 suppliers
1 buyer
31 suppliers
- Allergan Marlow
- Accord Devon
- Roche Products Garden City
- Sandoz Camberley
- Amgen Cambridge
- Napp Pharmaceuticals Cambridge
- Novo Nordisk Gatwick
- Pfizer Kent
- Vifor Pharma London
- Ipsen Slough
- Janssen Cilag High Wycombe
- Teva Castleford
- Almirall Uxbridge
- Merck Serono Feltham
- Chugai Pharma Chiswick
- Pharmacosmos Reading
- Merz Hemel Hempstead
- Eli Lilly Basingstoke
- Merck Sharpe & Dohme London
- Zentiva Pharma London
- Thornton & Ross Huddersfield
- Astrazeneca Luton
- Bristol Myers Squibb Uxbridge
- Glaxosmithkline London
- Sobi Swedish Orphan Biovitrum Cambridgeshire
- Celltrion Healthcare Slough
- Takeda London
- Aventis Pharma Reading
- Gedeon Richter London
- Organon Pharmaceuticals London
- Ucb Pharma Slough
Description
NHS Framework for the Midlands and East, Branded Medicines – Tranche A and Annual TrancheOffer reference number: CM/PHR/20/5602CM/PHR/20/5602/01 - NHS Framework for the Midlands and East, Branded Medicines – Tranche A. Period of framework: 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/20/5602/02 - NHS Framework for the Midlands and East Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
Lot Division
| 1 | CM/PHR/20/5602/01 - NHS Framework Mids and East, Branded Medicines–Tranche A CM/PHR/20/5602/01 - NHS Framework for the Midlands and East, Branded Medicines – Tranche A. Period of framework: 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months |
| 2 | CM/PHR/20/5602/02 - NHS Framework Mids and East Branded Medicines - Annual CM/PHR/20/5602/02 - NHS Framework for the Midlands and East Branded Medicines - Annual Tranche Products. |
Award Detail
| 1 | Allergan (Marlow)
|
| 2 | Accord (Devon)
|
| 3 | Roche Products (Garden City)
|
| 4 | Sandoz (Camberley)
|
| 5 | Amgen (Cambridge)
|
| 6 | Napp Pharmaceuticals (Cambridge)
|
| 7 | Novo Nordisk (Gatwick)
|
| 8 | Pfizer (Kent)
|
| 9 | Vifor Pharma (London)
|
| 10 | Ipsen (Slough)
|
| 11 | Janssen Cilag (High Wycombe)
|
| 12 | Teva (Castleford)
|
| 13 | Almirall (Uxbridge)
|
| 14 | Merck Serono (Feltham)
|
| 15 | Chugai Pharma (Chiswick)
|
| 16 | Pharmacosmos (Reading)
|
| 17 | Merz (Hemel Hempstead)
|
| 18 | Eli Lilly (Basingstoke)
|
| 19 | Merck Sharpe & Dohme (London)
|
| 20 | Zentiva Pharma (London)
|
| 21 | Thornton & Ross (Huddersfield)
|
| 22 | Accord (Devon)
|
| 23 | Roche Products (Garden City)
|
| 24 | Astrazeneca (Luton)
|
| 25 | Bristol Myers Squibb (Uxbridge)
|
| 26 | Amgen (Cambridge)
|
| 27 | Napp Pharmaceuticals (Cambridge)
|
| 28 | Pfizer (Kent)
|
| 29 | Glaxosmithkline (London)
|
| 30 | Janssen Cilag (High Wycombe)
|
| 31 | Teva (Castleford)
|
| 32 | Sobi Swedish Orphan Biovitrum (Cambridgeshire)
|
| 33 | Celltrion Healthcare (Slough)
|
| 34 | Takeda (London)
|
| 35 | Aventis Pharma (Reading)
|
| 36 | Eli Lilly (Basingstoke)
|
| 37 | Gedeon Richter (London)
|
| 38 | Organon Pharmaceuticals (London)
|
| 39 | Ucb Pharma (Slough)
|
Award Criteria
| price | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Options are available.
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-02d5e9
- FTS 004917-2022